European Osteoarthritis Therapeutics Market
European Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report, By Anatomy (Knee, Ankle, Hip, Hand, and Spine), By Drug Type (NSAIDs, Viscosupplementation Agents, Corticosteroids, and Analgesics) and Forecast, 2020-2026 Update Available - Forecast 2024-2030
European osteoarthritis therapeutics market is estimated to grow at a CAGR of 8.0% during the forecast period. Some pivotal factors encouraging market growth include the rising prevalence of arthritis and increasing demand for viscosupplementation agents. As per the National Institute for Health and Care Excellence (NICE), osteoarthritis is the cause of disability and the most common form of peripheral joint arthritis in the UK. It affects primarily the hand, knee, feet, and hip joints. In the UK, nearly 8.5 million people have painful joints due to osteoarthritis. This, in turn, is resulting in an increasing demand for osteoarthritis treatment. Analgesics is one of the drug types that is used for pain treatment; however, they don’t treat inflammation. This drug class works by stopping signals in the body that creates pain. Instances of analgesics include Acetaminophen (Tylenol) and Duloxetine (Cymbalta). Acetaminophen (Tylenol) is an over the counter (OTC) analgesic that can be administered orally as a tablet, gel capsule, or liquid concentration.
The market is segmented based on anatomy and drug type. Based on anatomy, the market is classified into the knee, ankle, hip, hand, and spine. Based on drug type, the market is segmented into NSAIDs, viscosupplementation agents, corticosteroids, and analgesics. During the viscosupplementation procedure, hyaluronic acid, gel-like fluid that is a naturally occurring lubricant, is injected into the knee joint. Hyaluronic acid facilitates the smoother movement of joints. It has less concentration in patients having knee osteoarthritis. DUROLANE (Q-Med) is one of the EU approved hyaluronic acid. It is the only hyaluronic acid product that is administrated as a single injection per treatment course, to improve mobility and diminish pain in patients with osteoarthritis of the hip or knee.
Some key players operating in the market include Pfizer Inc., Bayer AG, Zimmer Biomet Holdings, Inc., Sanofi S.A., and GlaxoSmithKline plc. In February 2020, GlaxoSmithKline plc declared the US FDA approval of Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID). It is an arthritis pain relief available as an OTC product to temporarily provide relief from arthritis pain in the knee, elbow, hand, ankle, wrist, or foot, in adults (18 years and older). With the approval of the US FDA, Voltaren Arthritis Pain becomes the first and only prescription-strength, NSAID topical gel for arthritis pain available OTC in the US. This approval will offer approximately 30 million Americans suffering from osteoarthritis OTC access to the topical treatment option.
Research Methodology
The market study of the European osteoarthritis therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
- European Osteoarthritis Therapeutics Market Research and Analysis by Anatomy
- European Osteoarthritis Therapeutics Market Research and Analysis by Drug Type
The Report Covers
- Comprehensive research methodology of the European osteoarthritis therapeutics market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the European osteoarthritis therapeutics market.
- Insights about market determinants which are stimulating the European osteoarthritis therapeutics market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Country
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. European Osteoarthritis Therapeutics Market by Anatomy
5.1.1. Knee
5.1.2. Ankle
5.1.3. Hip
5.1.4. Hand
5.1.5. Spine
5.2. European Osteoarthritis Therapeutics Market by Drug Type
5.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.2.2. Viscosupplementation Agents
5.2.3. Corticosteroids
5.2.4. Analgesics
6. Regional Analysis
6.1. UK
6.2. Germany
6.3. France
6.4. Spain
6.5. Italy
6.6. Rest of European
7. Company Profiles
7.1. Bayer AG
7.2. Ferring Pharmaceuticals
7.3. Fidia Farmaceutici S.p.A.
7.4. GlaxoSmithKline plc
7.5. Horizon Therapeutics plc
7.6. Kitov Pharmaceuticals Ltd.
7.7. Laboratorio Reig Jofre
7.8. Novartis International AG
7.9. Pfizer Inc.
7.10. Sanofi S.A.
1. EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
2. EUROPEAN KNEE OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
3. EUROPEAN ANKLE OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
4. EUROPEAN HIP OSTEOARTHRITIS THERAPEUTICS RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
5. EUROPEAN HAND OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
6. EUROPEAN SPINE OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
7. EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
8. EUROPEAN NSAIDs FOR OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
9. EUROPEAN VISCOSUPPLEMENTATION FOR OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
10. EUROPEAN CORTICOSTEROIDS FOR OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
11. EUROPEAN ANALGESICS FOR OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
12. EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
13. UK OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
14. UK OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
15. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
16. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
17. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
18. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
19. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
20. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
21. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
22. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
23. REST OF EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
24. REST OF EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
1. EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY ANATOMY, 2019 VS 2026 (%)
2. EUROPEAN KNEE OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
3. EUROPEAN ANKLE OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
4. EUROPEAN HIP OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
5. EUROPEAN HAND OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
6. EUROPEAN SPINE OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
7. EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY DRUG TYPE, 2019 VS 2026 (%)
8. EUROPEAN NSAIDs FOR OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
9. EUROPEAN VISCOSUPPLEMENTATION FOR OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY DRUG TYPE, 2019 VS 2026 (%)
10. EUROPEAN CORTICOSTEROIDS FOR OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
11. EUROPEAN ANALGESICS FOR OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
12. EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
13. UK OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
14. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
15. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
16. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
17. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
18. REST OF EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
